Physician profile
Sarah A King
NPI 1386140150
$2,241.90
in general payments reported to CMS, 2019-2025
29 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $401 · 2023: $605 · 2024: $501 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $402.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $305.04 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $198.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $148.98 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $135.36 | 2021-2025 | Minimed 780g |
| Amgen INC. | $101.58 | 2023-2025 | Evenity, Prolia, Repatha |
| Insulet Corporation | $95.42 | 2022-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $91.25 | 2021-2024 | |
| Corcept Therapeutics | $84.42 | 2024-2025 | Korlym |
| Cequr Corporation | $59.20 | 2023-2024 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $57.84 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $57.41 | 2022-2025 | |
| Radius Health, INC. | $55.00 | 2022-2025 | Tymlos |
| Abbvie INC. | $53.49 | 2022-2025 | |
| Ibsa Pharma INC. | $51.74 | 2021-2024 | Licart, Tirosint |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $48.12 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ipsen Biopharmaceuticals, INC | $44.60 | 2022 | |
| Mannkind Corporation | $40.59 | 2021-2024 | |
| Amryt Pharma Holdings LTD | $23.78 | 2023 | Mycapssa |
| Microtransponder, INC. | $23.49 | 2025 | |
| Sequel Med Tech, LLC | $22.51 | 2025 | Twiist |
| Pfizer INC. | $22.26 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2022 | |
| Kyowa Kirin, INC. | $20.83 | 2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $18.45 | 2024 | NP Thyroid 60 |
| Alvogen INC | $16.69 | 2023 | Teriparatide |
| Halozyme INC | $15.32 | 2023 | |
| Recordati_rare_diseases_inc. | $15.18 | 2024 | Isturisa |
| Amarin Pharma, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.